首页> 外文期刊>Bioorganic and Medicinal Chemistry Letters >Exploration of pyridine containing heteroaryl analogs of biaryl ureas as DGAT1 inhibitors.
【24h】

Exploration of pyridine containing heteroaryl analogs of biaryl ureas as DGAT1 inhibitors.

机译:含吡啶的含吡啶含吡啶的杂芳基作为DGAT1抑制剂的杂芳基类似物。

获取原文
获取原文并翻译 | 示例
           

摘要

The diacylglycerol acyltransferase enzyme, DGAT1, presents itself as a potential target for obesity as this enzyme is dedicated to the final committed step in triglyceride biosynthesis. Biphenyl ureas, exemplified by compound 4, have been reported to be potent hDGAT1 inhibitors. We have synthesized and evaluated 2-pyridyl and 3-pyridyl containing biaryl ureas as hDGAT1 inhibitors. Our aim was to incorporate a heteroaryl scaffold within these molecules thereby improving the cLogP profile and making these compounds more drug-like. Compounds within this series exhibited potent hDGAT1 inhibition when evaluated using an in vitro enzymatic assay. Selected compounds were also subjected to an oral fat tolerance test in mice where the percent triglyceride reduction versus a vehicle control was evaluated. Of the studied heteroaryl analogs compound 44 exhibited an in vitro IC(50) of 17nM and a plasma triglyceride reduction of 79% along with a 12-fold improvement in solubility over the biphenyl urea compound 4.
机译:双甘油甘油酰基转移酶DGAT1呈现为肥胖的潜在靶标,因为该酶专用于甘油三酯生物合成中的最终发生的步骤。据报道,通过化合物4举例说明的联苯脲是有效的HDGAT1抑制剂。我们已经合成和评估了含2-吡啶基和含3-吡啶基的Biaryl脲作为HDGAT1抑制剂。我们的目的是在这些分子中掺入杂芳基支架,从而改善螺纹曲线曲线并使这些化合物更具药物状。当使用体外酶测定法评估时,该系列内的化合物表现出效率的HDGAT1抑制。还对选定的化合物进行小鼠的口服脂肪耐受试验,其中评价甘油三酯百分比减少与载体对照的小鼠。研究的杂芳基类似物化合物44在17nm的体外IC(50)中,并血浆甘油三酯减少79%以及在联苯脲化合物4上溶解度的12倍改善。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号